Asset Details
Do you wish to reserve the book?
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Do you wish to request the book?
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
2016
Overview
Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interference with the CD47–SIRPα interaction synergizes with tumor-specific monoclonal antibodies to eliminate human tumor xenografts by enhancing macrophage-mediated antibody-dependent cellular phagocytosis (ADCP), but synergy between CD47 blockade and ADCP has yet to be demonstrated in immunocompetent hosts. Here, we show that CD47 blockade alone or in combination with a tumor-specific antibody fails to generate antitumor immunity against syngeneic B16F10 tumors in mice. Durable tumor immunity required programmed death-ligand 1 (PD-L1) blockade in combination with an antitumor antibody, with incorporation of CD47 antagonism substantially improving response rates. Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy.
Publisher
National Academy of Sciences
Subject
Adaptive Immunity - drug effects
/ Adaptive Immunity - immunology
/ Animals
/ Antibodies, Monoclonal, Murine-Derived - administration & dosage
/ Antibodies, Monoclonal, Murine-Derived - immunology
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - immunology
/ Cancer
/ Cancer Vaccines - administration & dosage
/ Cancer Vaccines - immunology
/ Female
/ Ligands
/ Male
/ Mice
/ Molecular Targeted Therapy - methods
/ Neoplasms, Experimental - immunology
/ Neoplasms, Experimental - pathology
/ Neoplasms, Experimental - therapy
/ Proteins
/ Rodents
/ Tumors
